SCHEMBL21991852

SCHEMBL21991852

COC(=O)C(C)C(C)Oc1ccc(Br)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.49
LMNA P02545 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 2/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21992562 0.86 TAS1R3 (0.51) KMT2AMEN1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21992597 0.85 LDHA (0.47) LDHALMNATDP1KMT2AMEN1
SCHEMBL23605998 0.84 KMT2A (0.50) LMNATDP1KMT2AMEN1MAPT
SCHEMBL24418990 0.84 KMT2A (0.50) LMNATDP1KMT2AMEN1MAPT
SCHEMBL24419039 0.84 KMT2A (0.50) LMNATDP1KMT2AMEN1MAPT
SCHEMBL24419111 0.84 KMT2A (0.50) LMNATDP1KMT2AMEN1MAPT
SCHEMBL24418969 0.84 KMT2A (0.50) LMNATDP1KMT2AMEN1MAPT
SCHEMBL21991837 0.83 KMT2A (0.48) LDHALMNATDP1KMT2AMEN1
SCHEMBL21991494 0.83 GAA (0.44) LMNAKMT2AMEN1MAPTRAB9A
SCHEMBL21991774 0.83 ALDH1A1 (0.53) LMNAKMT2AMEN1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 LDHA 3139/4885LMNA 4533/4885TDP1 1445/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 LDHA 3139/4885LMNA 4533/4885TDP1 1445/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 LDHA 3139/4885LMNA 4533/4885TDP1 1445/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 LDHA 3139/4885LMNA 4533/4885TDP1 1445/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 LDHA 3139/4885LMNA 4533/4885TDP1 1445/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 LDHA 3139/4885LMNA 4533/4885TDP1 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.